Revvity (RVTY) is higher after releasing first-quarter 2026 earnings and updating its outlook. The company posted revenue of $711.1 million (up from $664.8 million a year earlier) and adjusted EPS from continuing operations of $1.06 (up from $1.01), a combination that helped offset investor concerns about a more cautious full-year setup.

Beyond the quarterly beat on profitability, Revvity announced its intention to divest its Immunodiagnostics business in China, saying the unit represented about 6% of total company revenue in fiscal 2025. Revvity said it has signed a letter of intent with a prospective buyer, expects a definitive agreement in Q2 2026, and anticipates completing the divestiture in 2027, subject to regulatory approvals.

For full-year 2026 on a pro forma basis (excluding the business it intends to divest), Revvity forecast revenue of $2.81–$2.84 billion and adjusted EPS of $5.20–$5.30, with pro forma organic revenue growth expected at 3%–4%. The market move suggests investors are emphasizing the near-term execution and the portfolio simplification narrative, even as the updated outlook frames a more measured growth trajectory.